Treatment Outcomes of Slow Coagulation Transscleral Cyclopho
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to report treatment outcomes of slow coagulation transscleral cyclophotocoagulation (TSCPC) as an initial surgical intervention in pseudophakic glaucomatous patients.

Analysis included 74 pseudophakic patients with a diagnosis of glaucoma and no previous glaucoma surgeries. The primary outcome measure was surgical success, which was described as a reduction in IOP of more than 20% from baseline, no glaucoma reoperation, and no loss of light perception vision. Glaucoma drug use, visual acuity (VA), and complications are also secondary outcome measures.

Results:
--IOP decreased from 27.5±9.8 mmHg preoperatively to 16.1±6.3 mm Hg postoperatively.

--The preoperative number of glaucoma medications was 4.1±0.9 and 3.1±1.3 post-TSCPC.

--The cumulative probability of success at 1 and 2 years were 60.6 % and 58.5%, respectively.

--When patients were divided into 2 groups based on their baseline IOP being more than 21 mmHg (high group) or less than 21 mmHg (low group), success rates at 2 years were 64.9% and 45.5%, respectively.

--Mean logMAR VA changed from 0.70 ± 0.64 to 1.04±0.87 at the last follow-up visit.

--No serious complications were observed and most of the complications were mild and transient.

Finally, slow coagulation TSCPC has a good efficiency and safety profile as an initial surgical intervention in pseudophakic glaucomatous patients, particularly in patients with baseline IOP greater than 21 mm Hg.

Source: https://www.sciencedirect.com/science/article/abs/pii/S0002939421001926?dgcid=rss_sd_all
Like
Comment
Share